News
A new report looks at hiring trends © 2025 American City Business Journals. All rights reserved. Use of and/or registration ...
5d
Stocktwits on MSNJohnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug CaplytaJohnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...
By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often ...
2d
Zacks Investment Research on MSNFDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV PillMerck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...
Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...
The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.
The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...
Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...
3d
Clinical Trials Arena on MSNFDA approves Purespring’s application for Phase I/II trial of IgAN treatmentThe US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.
- NDA assigned a Target Action Date of February 25, 2026 - ...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results